Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NITROREDUCTASE: A PRODRUG‐ACTIVATING ENZYME FOR CANCER GENE THERAPY

1 Nov 2004

Abstract excerpt

1. The prodrug CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) is activated by Escherichia coli nitroreductase (NTR) to a potent DNA-crosslinking agent. 2. Virus-mediated expression of NTR in tumour cells sensitizes them to CB1954 in vitro and in vivo, providing the basis for a strategy of cancer gene therapy. 3. A phase I trial of CB1954 in cancer patients has been completed, documenting the pharmacokinetics and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15566399
DOI: 10.1111/j.1440-1681.2004.04085.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NITROREDUCTASE: A PRODRUG‐ACTIVATING ENZYME FOR CANCER GENE THERAPYPMID 15566399Read ↗

Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression ofE. coli nitroreductaseSemantic proximity Read ↗

Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.Semantic proximity Read ↗

Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954.Semantic proximity Read ↗

NTR 2.0: a rationally-engineered prodrug converting enzyme with substantially enhanced efficacy for targeted cell ablationSemantic proximity Read ↗

Leveraging Homologous Recombination Deficiency via the Repositioned Prodrug CB1954Semantic proximity Read ↗

Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.Semantic proximity Read ↗

The NTR/Prodrug Revolution: Tools for Controlling Cell Loss and RegenerationSemantic proximity Read ↗

The NTR/Prodrug Revolution: Tools for Controlling Cell Loss and RegenerationSemantic proximity Read ↗

Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.Semantic proximity Read ↗

Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model.Semantic proximity Read ↗

Genetic Prodrug Activation Therapy for Breast Cancer: A Phase I Clinical Trial oferbB-2–Directed Suicide Gene ExpressionSemantic proximity Read ↗

Antibody–Enzyme Fusion Proteins for Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.